-transparent.png){kind=logo}
We have examined the induction of murine non-specific killer cells in vivo and in vitro by purified recombinant human interleukin-2 (rIL-2), and compared their characteristics with respect to killing ability, cell surface phenotypes, and antibody-dependent cell-mediated cytotoxicity (ADCC). C57BL/6 spleen cells cultured with rIL-2 were remarkably cytotoxic against a variety of tumour cells in a 4-hr 51Cr-release assay. Treatment with various antibodies (anti-Thy 1, anti-Lyt 1, anti-Lyt 2, and anti-asialo GM1) plus complement (C) showed that anti-Thy 1 or anti-asialo GM1 antibody plus C removed a majority of killer activity (80% and 66%, respectively). In addition, an increase in ADCC was detected in the spleen cells cultured with rIL-2. These ADCC effector cells were indistinguishable from non-specific killer cells by the cell surface phenotypes. A single administration of rIL-2 in vivo induced only transient and marginal enhancement of non-specific killer activity of spleen cells in C57BL/6 mice. On the other hand, when 10 micrograms of rIL-2 were administered daily by bolus to C57BL/6 mice, the activity increased gradually for about 10 days and reached a plateau. This enhanced non-specific killer activity rapidly decreased and returned to normal by 72 hr after the administration was stopped. The non-specific killer cells induced in vivo in this manner were not only greatly cytotoxic against natural killer (NK)-sensitive tumour cells but were also significantly cytotoxic against NK-resistant tumour cells. Most of the killer activity (more than 90%) was specifically removed by treatment with anti-Thy 1 or anti-asialo GM1 antibody plus C. An increase in ADCC was detected concurrently with an increase in non-specific killer activity in vivo, and both effector cells were indistinguishable by their cell surface phenotypes. These results indicate that a majority of non-specific killer cells induced both in vivo and in vitro by rIL-2 have some common features. Our results also suggest that these cells belong to the same lineage as NK cells, although they are thought to be at different stages from resident NK cells.
S Hinuma, and
K Naruo, and
O Shiho, and
K Tsukamoto
April 1985,
Immunobiology,
S Hinuma, and
K Naruo, and
O Shiho, and
K Tsukamoto
January 1990,
The Journal of experimental medicine,
S Hinuma, and
K Naruo, and
O Shiho, and
K Tsukamoto
January 1986,
Folia biologica,
S Hinuma, and
K Naruo, and
O Shiho, and
K Tsukamoto
January 1990,
Annales de recherches veterinaires. Annals of veterinary research,
S Hinuma, and
K Naruo, and
O Shiho, and
K Tsukamoto
January 1991,
Cellular immunology,
S Hinuma, and
K Naruo, and
O Shiho, and
K Tsukamoto
February 1985,
Cellular immunology,
S Hinuma, and
K Naruo, and
O Shiho, and
K Tsukamoto
March 1985,
Cellular immunology,
S Hinuma, and
K Naruo, and
O Shiho, and
K Tsukamoto
April 1988,
Cancer research,
S Hinuma, and
K Naruo, and
O Shiho, and
K Tsukamoto
December 1995,
Immunology letters,
S Hinuma, and
K Naruo, and
O Shiho, and
K Tsukamoto
December 1989,
Journal of biological response modifiers,
